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The aim of the study was to evaluate the exhaled nitric oxide (FENO) in clinically
stable chronic obstructive pulmonary disease (COPD), its relationship to the severity
of the disease, pulmonary function, smoking status, reversibility of airflow
limitation, and ICS therapy.
The study was conducted in 47 patients with COPD and 40 healthy controls. Flow/
volume spirometry and FENO measurement were performed before and after 2
months of ICS therapy.
FENO were significantly elevated in current smokers and ex-smoking COPD
patients. In both groups of COPD patients inhaled corticosteroids (ICS) therapy
caused a significant decrease in FENO without significant changes in FEV1. A positive
correlation between initial FENO and postbronchodilator FEV1 (% predicted) was
observed in the group of ex-smoking COPD patients, but not in the currently smoking
COPD group. In both groups of COPD patients, the initial level of FENO correlated with
the reversibility of airway obstruction, the increase in postbronchodilator FEV1 and
the decrease in FENO following ICS treatment.
FENO increases in patients with stable COPD. ICS therapy decreased elevated FENO
levels in these patients without statistically significant changes in lung function. The
selection of COPD patients with increased FENO level and partial reversibility of
airway obstruction should be helpful in terms of proposed ICS treatment.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
7468373;
l (Z. Zietkowski).Introduction
Chronic obstructive pulmonary disease (COPD) is
a syndrome characterised by mucus hypersecre-
tion, lung destruction and progressive airflowed.
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tant role in the pathogenesis of COPD and it
correlates with an increase in the number of
macrophages, lymphocytes (mainly CD8) and neu-
trophils.2 An inflammatory destruction in the lungs
is induced by exposure to harmful dusts, exhausts
and cigarette smoke, and the latter has been found
to be the main risk factor for COPD.3 The airflow
obstruction in COPD is usually progressive, it may
be accompanied by bronchial hyperreactivity, and
it could be partially reversible.4
Corticosteroids are the best known anti-inflam-
matory drugs in the treatment of airway diseases.
However, the use of inhaled corticosteroids (ICS) in
the treatment of COPD is still controversial. They
do not counteract the reduction of FEV1 in most
COPD patients,5 but, in severe COPD, inhaled
corticosteroids reduce exacerbations and improve
the patient’s condition.6 The relationship between
dose and clinical improvement, patient selection,
and recommended time of treatment remain
unclear. Based on the available diagnostic tests it
is difficult to estimate long-term airway response
after short-term treatment with systemic corticos-
teroids in COPD patients.7 Simple, non-invasive
techniques for monitoring ICS therapy in COPD
patients are required.
Elevated levels of exhaled nitric oxide (FENO) are
observed in asthma patients, and these are
associated with generally accepted clinical markers
of airway inflammation.8 Anti-inflammatory treat-
ment with ICS in asthma patients reduces levels
of NO in exhaled air.9 The measurement of FENO
in patients with COPD provided conflicting
results.10,11
The aim of the present study was to evaluate the
exhaled nitric oxide level in patients with clinically
stable COPD, and its relationship to the severity of
the disease, pulmonary function, smoking status,
reversibility of airflow limitation and ICS therapy.Methods
Patients
The study was conducted in a group of 47 patients
with COPD (28 current smokers and 19 ex-smokers).
Forty healthy subjects (17 current smokers and 23
non-smokers) served as a control group.
COPD was diagnosed according to the criteria
recommended by the European Respiratory So-
ciety.12 All COPD patients were nonatopic and had
a history of chronic progressive symptoms, such as
breathlessness, cough, wheezing and sputum pro-duction. All patients were free from acute exacer-
bations and respiratory tract infections during the
past 2 months. Patients treated with inhaled or
systemic corticosteroids during the past 3 months
were excluded from the study. Chronic airflow
limitation was defined as FEV1/FVCo70% and
FEV1o80% of predicted values, before and after
400 mg of inhaled salbutamol. Thirty minutes after
salbutamol intake, the increase in FEV1 was less
than 12% and 200ml. Before the beginning of the
study patients were allowed to take short- and
long-acting b2 agonists and anti-cholinergic drugs.
Currently smoking COPD patients included in the
study had smoked more than 20 pack-years. The
ex-smoking COPD group had not smoked for at least
2 years.
Control volunteers were free of chronic or
recurrent respiratory symptoms, with no past
history of significant pulmonary disease. They were
nonatopic and had FEV1/FVC480% and FEV1480%
of predicted values. They were free of respiratory
tract infection within 2 months prior to the study
and from other significant illnesses known to affect
FENO measurements. Healthy volunteers from the
non-smoking group had never smoked and during
recent years had not been passive smokers. Healthy
volunteers from the smoking group had smoked for
more than 10 pack-years.
The Bioethics Committee of the Medical Uni-
versity of Bialystok granted ethical permission for
the research. Informed consent was obtained from
every patient entered into the study.Measurements
All COPD patients performed flow/volume spiro-
metry before and after 400 mg of salbutamol MDI via
Volumatic (Ventolin, GlaxoWellcome). Spirometry
was performed according to ATS standards13 using
a Master Screen Pneumo spirometer (Jaeger
Germany). Before the examination the patients
did not take any medications that could change
spirometry results (wash out periods: short-acting
b2 agonists—6 h, long-acting b2 agonists—24 h,
anti-cholinergic drugs—24 h). Healthy volunteers
also performed flow/volume spirometry.
Exhaled nitric oxide (FENO) was measured in all
COPD patients and healthy subjects by the chemi-
luminescence technique using the Sievers 280i NO
Analyzer (USA). The measurement was performed
according to the criteria listed in the American
Thoracic Society/American Lung Association
Recommendations for On-line Measurement of
Exhaled Nitric Oxide in Adults and the Recommen-
dations for On-line, Offline and Nasal Expired Nitric
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ments were carried out at an expiratory flow of
50ml/s. To produce a stable NO level for 3 s, the
duration of exhalation lasted at least 6 s. All
subjects had three recorded NO measurements.
Repeated measurements were performed until 3
values varied by less than 10%. The mean value of
the three measurements was evidenced as the final
FENO level.
The COPD patients were administered inhaled
budesonide (800 mg/day, Pulmicort Turbuhaler, As-
traZeneca). After 2 months of ICS therapy, post-
bronchodilator flow/volume spirometry and FENO
measurement were performed again.Analysis
The data was normally distributed, therefore
statistical analyses were completed using the
Student’s t-test (Statistica computer programme).
All values were expressed as mean7SD, and P
valueso0.05 were considered significant. The
relationship between studied parameters was as-
sayed by correlation. The Pearson’s linear correla-
tion coefficient was used.Results
Characteristics of the studied COPD patients and
healthy controls are presented in Table 1. In the
smoking and ex-smoking COPD patients no differ-
ences were observed in age, duration and severity
of the disease (% predicted postbronchodilator
FEV1). The comparison of FEV1 among healthyTable 1 Characteristics of the studied groups.
Characteristics Smoking COPD
Age years 60.279.4
Sex male/female 21/7
History of smoking
Duration of smoking/years 32714
Pack-years 36713
Ex-smoker since/years
Duration of symptoms/years 1377
FEV1 (% pred)
Postbronchodilator FEV1(% pred) 47.07714.55
D FEV1 (%) 6.673.7
ml 68.2738.3
Data are presented as mean7SD.
FEV1—forced expiratory volume in 1 s.
D FEV1—increase in FEV1 after inhaling 400mg of salbutamol.control subjects showed statistically significant
lower values in the smoking group (smokers
95.4776.1% predicted vs. non-smokers 108.717
10.78% predicted; P ¼ 0:0009). COPD patients had
significantly lower values of FEV1 as compared to
healthy controls (Po0:0001), and were older and
had more pack-years than healthy volunteers
(Po0:0001). The currently smoking COPD subjects
smoked significantly more pack-years than ex-
smoking subjects (P ¼ 0:02) (Table 1).
The exhaled NO level (FENO) in studied groups is
shown in Fig. 1. In the smoking patients FENO was
significantly higher in the COPD group than in
healthy volunteers (10.6174.6 ppB vs. 7.1672.16
ppB; P ¼ 0:02). Also, in ex-smoking COPD patients,
FENO was significantly elevated in comparison to
never smoking healthy controls (15.6678.59 ppB
vs. 11.1472.51 ppB; P ¼ 0:04). In COPD patients
the FENO level was higher in the ex-smokers than in
the smoking group (P ¼ 0:02). In the healthy
control groups, patients without a smoking history
had a higher level of FENO than smokers (P ¼ 0:0003)
(Fig. 1).
Fig. 2 shows the influence of a 2-month-course of
ICS therapy on FENO levels in COPD patients. ICS
treatment significantly reduced the FENO level in
both groups: the currently smoking COPD patients
(10.6174.6 ppB vs. 9.6472.74 ppB, before and
after ICS therapy, respectively; P ¼ 0:02), and the
COPD ex-smokers (15.6678.59 ppB vs. 12.0473.2
ppB, before and after ICS therapy, respectively;
P ¼ 0:003). It should be underlined that a signifi-
cant reduction in FENO was observed only in patients
with an initially high FENO level (Fig. 2). ICS therapy
did not increase significantly postbronchodilator
FEV1 (% predicted) (current smokers: 47.07714.55Ex -smoking COPD Healthy control
Non-smoking Smoking
61.278.1 42.5716.0 53.278.8
14/5 12/11 11/6
22711
28712 0 2077
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1178
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Figure 1 The exhaled NO levels in the groups of COPD patients and healthy volunteers.
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Figure 2 The influence of a 2-month-course of ICS therapy on FENO level in COPD patients.
The influence of ICS on FENO in stable COPD 819vs. 48.60714.5, before and after ICS therapy,
respectively; P ¼ 0:072; ex-smokers: 48.9715.3
vs. 49.8715.54, before and after ICS therapy,
respectively; P ¼ 0:073).
In the group of smoking COPD patients a
significant negative correlation was found between
the amount of smoked cigarettes (pack-years) and
airway obstruction (% predicted postbronchodilator
FEV1) (r ¼ 0:43; P ¼ 0:02). By contrast, this was
not observed in the ex-smokers COPD group
(r ¼ 0:19; P ¼ 0:41). No significant correlation
was noticed between the amount of pack-
years and FENO concentration (current smokers: r ¼
0:15; P ¼ 0:44; ex-smokers: r ¼ 0:01; P ¼ 0:94),
and between the pack-years and the extent of the
reversibility of airways obstruction (current smo-
kers: r ¼ 0:02; P ¼ 0:9; ex-smokers: r ¼ 0:11;
P ¼ 0:63).A statistically significant correlation between
initial FENO levels and postbronchodilator FEV1
(% predicted) was observed in the group of ex-
smokers COPD patients (r ¼ 0:47; P ¼ 0:04), but not
in currently smoking COPD patients (r ¼ 0:27;
P ¼ 0:15) (Fig. 3). In both groups of COPD patients,
the initial level of exhaled NO correlated with the
airway obstruction reversibility before ICS therapy
(current smokers: r ¼ 0:65; P ¼ 0:0001; ex-smokers:
r ¼ 0:76; P ¼ 0:0001) (Fig. 4), the increase in
postbronchodilator FEV1 after ICS therapy (current
smokers: r ¼ 0:72; P ¼ 0:0001; ex-smokers: r ¼
0:73; P ¼ 0:0003) (Fig. 5) and the decrease in
FENO following ICS treatment (current smokers: r ¼
0:88; Po0:0001; ex-smokers: r ¼ 0:95; Po0:0001)
(Fig. 6). Also in both COPD groups, the reversibility of
airway obstruction after inhaled salbutamol corre-
lated with the increase in postbronchodilator FEV1
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Figure 3 Correlation between initial FENO level and postbrochodilator FEV1 (% predicted) in COPD patients.
Figure 4 Correlation between initial FENO level and the reversibility of airway obstruction in COPD patients.
Z. Zietkowski et al.820after ICS therapy (current smokers: r ¼ 0:6; P ¼
0:0006; ex-smokers: r ¼ 0:72; P ¼ 0:0004) (Fig. 7).Discussion
In patients with asthma, the marked elevation of
exhaled NO is thought to reflect eosinophilic
airways inflammation and stimulation of inducible
nitric oxide synthase (NOS).15 In contrast toasthma, eosinophils are not prominent cells in-
volved in the inflammatory process in COPD. In
these patients inflammation is characterised by an
increase in macrophages, T-lymphocytes and neu-
trophils.16 However, an increase in sputum eosino-
phils and eosinophilic cationic protein (ECP) in
some COPD patients has also been observed,
particularly during exacerbations17 and when the
patients have concomitant asthma.18,19
Previous studies of exhaled NO in COPD patients
have yielded contradictory results, possibly due to
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Figure 5 Correlation between initial FENO levels and the increase in postbronchodilator FEV1 after ICS therapy.
Figure 6 Correlation between initial FENO levels and the decrease in FENO after ICS therapy.
The influence of ICS on FENO in stable COPD 821small groups of patients, prior treatment, unclear
inclusion criteria or patients’ smoking status.10,11,20
Maziak et al. have demonstrated that exhaled NO
level was increased in patients with unstable COPD,
suggesting that exhaled NO is a marker of COPD
instability.21 The aim of the present study was to
evaluate the initial exhaled NO level and its
possible changes during ICS therapy in stable COPD
patients with a precisely defined smoking status.
Our results showed a significant increase in the
exhaled NO level in patients with stable COPD
(without corticosteroids therapy), both current and
ex-smokers as compared to smoking and non-smoking healthy subjects. Thus, we confirmed and
extended a previous study pointing to the role of
exhaled NO in the pathogenesis of COPD.11,22 The
initial exhaled NO level was positively correlated
with FEV1 (% predicted) in ex-smokers, but not in
the current smoking COPD patients. This discre-
pancy may reflect the extent of airway obstruction
caused by continuous exposure to cigarette
smoke.22
The exhaled NO was significantly reduced in
current smokers as compared to the levels mea-
sured in ex-smokers or non-smoking control which is
in line with a previous report showing that tobacco
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Figure 7 Correlation between the reversibility of airway obstruction and increase in postbronchodilator FEV1 after ICS
therapy.
Z. Zietkowski et al.822smoke reduces exhaled NO:23 firstly, because of
chronic damage in NO-producing cells in the
airway; secondly, by influencing NO metabolism;
and thirdly, by down regulation of NOS due to high
NO concentration present in cigarette smoke.22,24
It is also possible that the chronic effects of
smoking, such as epithelial shedding, squamous
metaplasia, and mucus hypersecretion affects NO
production, which persists even after cessation of
smoking.25 The increased NO level in ex-smoking
patients clearly shows that the cessation of smok-
ing does not result in resolution of the inflamma-
tory process in the airways and suggests that there
are other mechanisms than cigarette smoke re-
sponsible for maintaining the inflammation once it
has been established. We did not observe any
correlations between exhaled NO level and smoking
history expressed as pack-years in smoking and
non-smoking COPD patients as well as smoking
healthy subjects; however in the smoking COPD
group, pack-years correlated negatively with air-
way obstruction.
In the present study, in clinically stable COPD
patients, partial reversibility of airflow limitation
after b2 agonist was associated with an increase in
the exhaled NO level. We have found a positive
correlation between exhaled NO and the degree of
reversibility in both groups of COPD patients,
smokers and ex-smokers. These results confirm
previous reports showing that partial reversibility
is associated with increased exhaled NO and
sputum eosinophilia.26 Complete reversibility of
airflow limitation is typical for asthma, but par-
tially reversible airflow limitation may be presentin some patients with COPD. These patients may
have a positive response to inhaled corticosteroids
treatment in contrast to patients without reversi-
ble airflow limitation.26
It is conceivable that the elevated NO level in
COPD patients reflects an inflammatory process in
the airway, aggravated by expression of numerous
inflammatory genes caused by amplification of the
normal pulmonary inflammatory response to irri-
tants or latent virus infection.1 In our study, two
months of ICS therapy in stable COPD patients
significantly reduced exhaled NO levels, pointing
out the anti-inflammatory mechanism of ICS action.
This is in contrast to the results of Maziak et al. that
found significantly higher NO levels in COPD
patients treated with ICS than in the steroid naı¨ve
group.21 This discrepancy could be explained by the
small number of subjects taking ICS and the marked
differences in disease severity between studied
groups in the Maziak paper, which included most of
the unstable patients with the steroid group as
distinguished from the present clinically stable
COPD subjects.
From the present study it is likely that the COPD
airway inflammation is corticosteroid sensitive.
Inhaled corticosteroids may decrease markers of
inflammation, among others protein C (CRP), but
the precise mechanism of this action needs to be
established.27 The marked reduction in exhaled NO
was observed in patients with a higher baseline NO,
suggesting that this group of patients most likely
profit from inhaled corticosteroids treatment. As it
is in asthma,28,29 the reduction in exhaled NO was
not followed by a significant increase in FEV1. One
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level in the present study could be related to the
concomitant asthma, since all the patients were
free from exacerbation. Although, in all COPD
patients the increase in FEV1 after salbutamol
intake was less than 12% and 200ml, subjects with
increased exhaled NO and some response to a
bronchodilator may share some of the functional
and pathologic features of asthma, especially the
fact that a positive correlation between the
reversibility of airway obstruction and an increase
in FEV1 after ICS therapy has been observed.
Moreover, the initially increased exhaled NO posi-
tively correlated with the increase in FEV1 after ICS
treatment.
One possible limitation of our study could be
the lack of placebo treated COPD patients, but
this was not a randomised, double-blind, placebo-
controlled, crossover study. In our clinical practice
we estimate FENO in COPD patients that are not
treated with inhaled corticosteroid. In this group
of patients in stable disease we did not observe
changes in FENO. Based on the above and also
literature data that confirmed lack of changes
in FENO in COPD patients treated with placebo,
30
we did not include those patients into the study.
In the present study, in the group of ex-smok-
ing COPD patients, two subjects had much higher
initial exhaled NO levels than the others, and
the decrease in NO levels in these two was
much more pronounced. To avoid statistical bias
we removed these individuals from the statistical
analysis, but it did not change the reached
conclusion (13.2774.9 ppB vs. 11.572.8 ppB,
before and after ICS therapy, respectively;
P ¼ 0:01).
We conclude that exhaled nitric oxide is in-
creased in patients with stable COPD. ICS therapy
decreased elevated exhaled NO levels in these
patients without statistically significant changes in
lung function. The selection of COPD subjects with
increased exhaled NO level and partial reversibility
of airway obstruction should be helpful in terms of
proposed ICS treatment.References
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